Vuse makes waves as the first global carbon neutral vape brand cataniaoggi.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cataniaoggi.it Daily Mail and Mail on Sunday newspapers.
Thai Union Launches Thailandâs First Sustainability-Linked Bond
Ground-breaking bond reaffirms Thai Union s strategic commitment to sustainability throughout its business
New product builds on Thai Union s Blue Finance portfolio following the Sustainability-Linked Loan launched in February 2021
BANGKOK - July 21, 2021 - Thai Union Group PCL. (Thai Union), the world s leading seafood processor, has successfully priced a THB 5 billion seven-year senior, unsecured Sustainability-Linked Bond (SLB) for institutional investors. The SLB carries an interest rate of 2.47 %. p.a. and was issued on July 20, 2021.
This is the first SLB that has been launched in Thailand and follows the launch of Thai Union s inaugural Sustainability-Linked Loan (SLL) in February 2021, further demonstrating the Company s ongoing commitment to its ESG principles. It is another significant step forward for Blue Finance-financing for projects benefiting oceans-and the seafood industry as a whole.
F. Hoffmann-La Roche Ltd: FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes need for new treatment options
1
Ib
This is the 11th Breakthrough Therapy Designation for Roche s
haematology
Venclexta demonstrating its potential across multiple blood cancers
Basel, 21 July 2021 - Roche] study is a phase Ib, open-label, non-randomised, multicentre, dose-finding study evaluating Venclexta/Venclyxto (venetoclax) in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndromes (MDS) comprising a dose-escalation portion and a safety expansion portion. The primary objectives of the study are to assess the safety profile and pharmacokinetics and determine the recommended phase II dose and dosing schedule of Venclexta/Venclyxto in combination with azacitidine. The response criteria specified in the M15-531 study are based on the modified Internatio
F. Hoffmann-La Roche Ltd: Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
casirivimab
hospitalised patients
Basel, 20 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve(casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death. In addition, its ability to retain activity against emerging variants, including the Delta variant, has been demonstrated in preclinical studies, said Levi Garraway, M.D., Ph.D., Roche s Chief Medical Officer and Head of Global Product Development. Today s ap
CSRWire - Three Post COVID-19 Resilience Trends to Watch csrwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from csrwire.com Daily Mail and Mail on Sunday newspapers.